ClinicalSayre focuses on co-development of novel assets with potential licensors. Sayre co-invests in clinical studies for US, EU and Japan approved drugs once they are mandated by the health authorities. We design clinical studies with pharmaco-economic and Quality of Life (QoL) parameters to help lower hospital stay & costs, and improve patient and caregiver QoL. Our studies tailor clinical response differences in Indian patients to help with “therapy customization”.